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Parkinson’s Disease (PD) is a neurodegenerative disorder 
affecting approximately 1-2% of the population at 60 years of age.1 
Symptoms include impaired motor function, tremor, rigidity, 
impaired balance and speech. The pathological hallmarks for PD 
include a reduction of dopaminergic neurons and dopamine 
secretion in the substantia nigra pars compacta region of the brain 
and the formation of Lewy bodies and intracellular fibrils in 
neurons.  Current therapies are limited to management of the 
symptoms associated with reduced dopamine signalling, such as 
L-DOPA therapy which increases the levels of dopamine in the 
striatum.2 These treatments have unpleasant side-effects and 
moreover, they do not address the underlying cause. Therefore, a 
disease modifying therapy remains a significant unmet medical 
need for PD. 
Although the majority of cases of PD are sporadic, it has been 
established that mutations in the LRRK2 gene are commonly 
associated with cases of familial PD.3 The most prevalent mutation 
in the protein is G2019S,4 which is present in the kinase domain 
and is associated with increased kinase activity in biochemical and 
cellular assays. It has been hypothesized that the increased kinase 
activity may be associated with the neurodegeneration and that 
inhibition of LRRK2 may slow the progression of the disease. 
There has been considerable interest in this target with a number 
of groups reporting their LRRK2 inhibitor programs.5 In this 
communication we describe the development of a novel series of 
azaindazole LRRK2 inhibitors. 
Our high throughput screening campaign at LifeArc identified 
a 5-azaindazole derivative 1. This was an attractive hit, owing to 
its low MW, good ligand efficiency (LE), lipophilic ligand 
efficiency (LLE) low PSA and a CNS MPO score of 4.7 with 
significant potential for further optimization (Figure 1).6
Figure 1
We initially focused our attention on varying the 4-
chlorobenzyl group (Table 1). An early observation was that the 
4-chloroaniline derivative 2 resulted in a significant gain in 
potency, therefore a range of anilines and amino heterocycles were 
synthesized (entries 3-7). The most potent example being the 4-
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Parkinson’s disease is a relatively common neurological disorder with incidence increasing with 
age. Present treatments merely alleviate the symptoms and do not alter the course of the disease, 
thus identification of disease modifying therapies represents a significant unmet medical need. 
Mutations in the LRRK2 gene are risk-factors for developing PD and it has been hypothesized 
that the increased kinase activity of certain LRRK2 mutants are responsible for the damage of the 
dopaminergic neurons, thus LRRK2 inhibitors offer the potential to target an underlying cause of 
the disease. In this communication, we describe hit-to-lead medicinal chemistry program on a 
novel series of 5-azaindazoles. Compound 1, obtained from high-throughput screening was 
optimized to a highly potent, selective series of molecules with promising DMPK properties. 
Introduction of heterocycles at the 3-position were found to significantly increase the potency and 
kinase selectivity, whilst changes to the 4-chlorobenzyl group improved the physicochemical 
properties. Our series was licensed to a major pharmaceutical company for further development.
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methyl aniline derivative 4, however this compound was found to 
have modest microsomal stability. Although the heterocyclic 
analogues (5-7) had improved physicochemical properties, a loss 
in potency for LRRK2 was observed, with the 3-pyridyl derivative 
5 being inactive. A range of non-aromatic amines were also 
investigated. Directly linked heterocycloalkyl amines, such as the 
morpholine 8 generally had weak potency, however, the 
cyclohexyl derivative 9 showed a significant boost in potency 
compared to the hit. Gratifyingly, this compound also had 
reasonable microsomal stability, and suggested good CNS 
penetration in mice with a total brain-plasma ratio of 4:1. The 
kinase selectivity (Figure 2) was surprisingly good considering the 
small size of this compound and was significantly better than the 
aniline derivative 4. Further cycloalkylamino derivatives were also 
investigated and it was found that reducing the ring-size (entries 
11-13) resulted in a progressive loss of potency. Methylation of 
the cyclohexylamino group (entry 10) resulted in a significant 
potency loss. Linear and branched aliphatic amines were also 
investigated for example, 14-16, in general these compounds had 
weak affinity, with the exception of the isobutyl derivative 16. Of 
all the amino derivatives that were synthesized, the 4-
tetrahydropyranyl derivative 17 had the optimal balance of 
potency and microsomal stability. Furthermore, this compound 
was found to have good CNS penetration in mice, with a brain-
plasma ratio of 1.6:1. 
A range of ether derivatives were also investigated, and in 
general these were found to be significantly more potent than the 
corresponding amino derivatives. For example, the cyclohexyl 
derivative (18) showed a 6-fold increase in potency compared to 
the amino derivative. On the other hand, these compounds were 
found to have reduced microsomal stability compared to their 
amino counter-parts, possibly due to their increased lipophilicity. 
An attempt to reduce the lipophilicity by incorporation of a basic 
nitrogen in the ring (20) resulted in a dramatic loss in potency. 
However, the more polar tetrahydropyranyl and tetrahydrofuranyl 
derivatives (19 and 25) was found to have significantly improved 
microsomal stability.
Of the 3-methyl derivatives, compounds 17 and 19 were found 
to have the best overall balance of potency, selectivity and 
microsomal stability, which is also reflected in having the highest 
LLEs of 5.5 and 5.6 respectively.
  
Table 1. 4-Position SAR of some representative examples
MeR
4
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H
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Entry R4
LRRK2
IC50 
(µM)a
cLogP 
/LLE
HLM / 
MLM
% turn.b
Entry R4
LRRK2
IC50 
(µM)a
cLogP 
/LLE LogD7.4
HLM / 
MLM
% turn.b
2 0.39 3.6/3.9 -/- 14 0.88 2.0/4.1 - -/-
3 0.097 3.1/3.9 13 / 28 15 2.4 2.0/3.6 - -/-
4 0.15 3.3/3.5 -/- 16 0.30 2.5/4.0 - 6 / 9
5 >10 1.7/ - -/- 17 0.19 1.1/5.5 1.2 0 / 4
6 0.83 1/5.1 -/- 18 0.067 4.0/3.2 >4 25 / 37
7 0.38 2.4/4.0 -/- 19 0.13 1.3/5.6 2.2 8 / 11
8 3 0.5/5.0 -/- 20 1.9 1.7/4.0 - -/-
9 0.39 3.2/3.2 7 / 13 21 0.44 1.9/4.4 - -/-
10 1.6 3.5/2.3 -/- 22 0.068 3.2/4.0 - 2 / 24
11 0.41 2.6/3.8 2 / 10 23 0.086 2.9/4.2 - 31 / 42
12 0.53 2.1/4.1 -/- 24 0.17 3.5/3.2 - 22 / 41
13 4.7 1.5/3.8 -/- 25 0.25 1.2/5.4 - 0 / 13
a  Radiometric assay using G2019S LRRK2 protein from Invitrogen. The values quoted are the mean of at least 2 experiments and with a range of < 25 % of the 
mean. b Values relate to % turnover of compound following in vitro incubation with human liver microsomes (HLM) for 40 min or mouse liver microsomes 
(MLM) for 30 min.
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Table 2. Selection of 3-heteroaryl analogues.
R4 R3
N
H
N
N
Entry R4 R3 LRRK2 IC50 (µM)a
PSA 
(Å2) cLogP/LLE mLogD7.4
HLM / MLM
% turn.
26 0.13 71 2.8/4.1 2.7 21 / 19
27 0.11 71 3.7/3.3 3.2 23 / 43
28 0.17 81 2.2/4.6 - -/-
29 0.41 81 2.1/4.3 - -/-
30 0.095 88 0.9/6.2 - 17 / 11
31 0.002 69 3.9/4.8 3.7 36 / 66
32 0.011 78 1.8/6.2 - 21 / 20
33 0.004 78 2.4/6.0 - -/-
34 0.015 78 2.3/5.5 - -/-
35 0.012 85 1.1/6.7 - 43 / 19
a  Radiometric assay using G2019S LRRK2 protein from Invitrogen. The values quoted are the mean of at least 2 experiments and with a range of < 25 % of the 
mean. b Values relate to % turnover of compound following in vitro incubation with human liver microsomes (HLM) for 40 min or mouse liver microsomes 
(MLM) for 30 min. Values given are the mean of at least two experiments.
In order to improve the potency further, we turned our attention 
to the 3-position (Table 2). An early observation led us to identify 
that heterocycles, such as pyrazoles (26-29) and the 
morpholinopyridine  30 gave a modest potency boost compared to 
the corresponding methyl derivatives. The real breakthrough came 
when switching to the ether analogues (31-35. The cyclohexyloxy 
derivative 31 displayed a 55-fold boost in potency compared to the 
corresponding cyclohexylamino derivative 27. Unfortunately this 
compound and related analogues suffered from poor microsomal 
stability, possibly due to the relatively high LogD. Switching to 
the 4-tetrahydropyranyl ether, yielded compounds with improved 
physicochemical properties, such as the isopropyl pyrazole 32 
pyridylmorpholine 35.
 Figure 2 shows the selectivity data for a selection of compounds 
against a panel of 59 protein kinases. The rescaled geometric mean 
(RGM) gives an indication of how selective the compound is, and 
a score of >0.7 is considered to be highly selective.7 The 4-anilino 
derivatives, such as 4 were found to have inferior selectivity to the 
corresponding cyclohexylamino derivative 9. Interestingly the 4-
THP derivatives appear to be more selective than the 
corresponding 4-cyclohexyloxy analogues (18 versus 19), which 
is reflected in a marked improvement of the RGM. Gratifyingly 
the selectivity of the 3-heteroaryl analogues, including 32 and 35 
improved dramatically. The improvement in selectivity is due to 
LRRK2 possessing a leucine residue (L1949) at the hinge region 
which can easily accommodate compounds with a wide range of 
larger substituents on the 3-position. Sequence alignment carried 
out by Genentech confirms that the majority of kinases possess 
larger residues, such as phenylalanine or a tyrosine at the same 
position,8 which can easily accommodate compounds bearing the 
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3-methyl substituent, such as 18 and 19. Extending out from the 3-
position results in an unfavourable steric clash with these Phe and 
Tyr residues (figure 2B). We carried our own sequence alignments 
of LRRK2 with significant kinases inhibited by compounds 18 and 
19, including RSK1, ROCK2, PIM1, GSK3β, CDK2 and MSK1 
using the sequence alignment tool in BioLuminate 1.9. 
Comparison of the selectivity data of 19 and 32 backs up this 
hypothesis: kinases most significantly inhibited by compound 32 
are PIM1 (77%) and GSK3β (90%), both of which also possess 
Leu residues at this position. On the other hand, kinases bearing 
larger residues such as ROCK2(Tyr), CDK2(Phe) and MSK1(Tyr) 
were significantly inhibited by 18 and 19 but had much lower 
inhibition by 32 and 35.
Compound
LRRK2 
IC50 (µM)
Concentration 
(µM)
RGM Score
4 0.38 10 0.57
9 0.39 10 0.61
18 0.066 10 0.36
19 0.13 10 0.59
32 0.011 1 0.74
35 0.012 1 0.92
Kinase Selectivity Heat Map
% Kinase inhibition >90 75-90 60-75 50-60 <50
Figure 2 Kinase selectivity heat map for a selection of compounds against a panel of 59 protein kinases at the specified 
concentration. The Rescaled geometric mean gives a numerical score between 0.1 (highly promiscuous) to 1 (highly selective). 
Figure 3A shows docking of key compounds into the hinge 
region of a LRRK2 homology model. We believe that the indazole 
forms two H-bonding interactions with E1948 and A1950 at the 
hinge, with the pyrido ring occupying the hydrophobic pocket in 
close proximity to the M1947 gatekeeper residue. The heterocycle 
coming off the 3-position of the core forms favourable interactions 
with the shallow hydrophobic pocket approaching the solvent 
channel. Ether derivatives, such as 32 appear to position the 
tetrahydropyranyl ring more tightly within the pocket under the 
glycine-rich loop and becoming less solvent exposed than the 
amine derivatives, such as 28. In this case the THP-ring appears to 
rotate further out of plane with the core and forms a less favourable 
interaction with protein. The improved selectivity of compounds 
with larger substituents in the 3-position can be rationalised by 
mutation of the L1949 residue to a Y (Figure 3B). Relatively few 
kinases, including LRRK2 have small or medium sized residues at 
this position which can easily accommodate bulky heterocyclic 
substituents. On the other hand, the majority of kinases bear larger 
phenylalanine or tyrosine residues in the same position which form 
unfavourable steric interactions with these ligands.  To further 
confirm the proposed hinge-binding mode we investigated a range 
of single point changes on the core (Table 3). Removal of the H-
donor at N1 was not tolerated, as both the N-methyl azaindazole 
(36) and the 5-azabenzisoxazole (37) show a complete loss of 
activity for LRRK2. Removal of the nitrogen at the 2-position (38) 
was also inactive. The observation that the 6-azaindazole (39) 
retained some activity suggests that it is unlikely that 5-aza 
nitrogen is involved in hinge-binding.  Furthermore, our proposed 
binding mode is consistent with X-ray crystal structures reported 
for 5- and 6-substituted indazoles complexed to other kinases (see 
PDB: 5L3A (JAK2), 3ZLY (MEK), 2UZU (AKT).
 
  
Figure 3 A) Predicted binding mode of 28 (dark green) and 32 (orange) to ATP-binding site of LRRK2 homology model; B) Predicted binding modes of 17 
(yellow) and 35 (purple) to ATP-binding site of LRRK2 homology model; the LRRK2 residues are shown in light green and mutated L1949Y residue is shown 
in black which exists in, for example ROCK2. Extending out from the 3-position of the azaindazole is well tolerated in LRRK2 but clashes with Y and F hinge-
residues and hence these compounds are more selective. These homology models were generated using the Prime module of Schrodinger Suite 7 and were based 
on the crystal structure of JAK2 (PDB: 1YVJ). Dockings were carried out using GlideSP1 with H-bonding constraints to E1948 and A1950.
(A)
(B)(A)
  
Scheme 1. (a) i. MeMgBr, THF, -78 ⁰C to -20 ⁰C, 73%; ii.TPAP, NMO, DCM, molecular sieves, rt, 80%; (b) N2H4.H2O, rt, 64%; (c) HNR1R2, 
n-butanol or DME, microwave, 190 ⁰C; (d) HNR1R2, HCl, n-butanol, microwave, 190 ⁰C; (e) R3OH, NaH, dioxane, rt, then 42, microwave, 180 
⁰C; (f) i. N2H4.H2O, rt, 64%; ii. I2, KOH, dioxane, 70 ⁰C, 61%; (g) p-methoxybenzylchloride, KOH, DMF, rt, 93%; (h) HNR1R2, HCl, n-butanol, 
microwave, 190 ⁰C; (i) i. Boronic acid or ester, Pd(dppf)Cl2, 2M Na2CO3, dioxane, 90 ⁰C; ii. TFA, 70 ⁰C; (j) Triphenylmethylchloride, NaH, 
DMF, 0 0C – rt, 96%; (k) ROH, NaH, Dioxane, 0 ⁰C, then 45 microwave, 185 ⁰C; (l) i. Boronic acid or ester, Pd(dppf)Cl2, 2M Na2CO3 dioxane, 
90 ⁰C; ii. TFA, DCM, rt; (m) i. NaH, MeI, DMF, rt, 65%; ii. Cyclohexylamine, n-BuOH, microwave, 190 ⁰C, 2h, 38%; (n) i. NH2OH.HCl, 
pyridine, reflux, 32%; ii. Pd(OAc)2, dppf, NaOtBu, 50 ⁰C, 21%; (o) Cyclohexylamine (neat), 80 ⁰C, 6h, 64%.
Scheme 2. (a) N2H4.H2O, 2-methoxyethanol, 125 ⁰C, 71%; (b) propionaldehyde, EtOH, reflux, 45%; (c) Ph2O, reflux, 7h, 22%; (d) i. POCl3, 65 
oC, 16h, 81%; ii. iPr2NEt, NMP, 150 oC, 3%; (e)  i. MeMgBr, THF, -78 ⁰C, 61%; ii. TPAP, NMO, DCM, molecular sieves, rt; iii. N2H4.H2O, n-
BuOH, 200 ⁰C, microwave, 30 min., 51%; iv. PMBCl, KOH, DMF, rt, 70%; (f) i. Pd2(dba)3, xantphos, NaOtBu, cyclohexylamine, dioxane; ii. 
AlCl3, toluene, 50 oC, 4h, 12% (2 steps).
Table 3. Selection of core modifications to probe the hinge-
interaction
Entry Compound LRRK2 IC50 (µM)a
26-30
(k)
1-17 18-25
31-35
(m)
(n)
37
3642
(b)
(o)
46
(j)
40
(i)(h)
(f)
(g)
(l)
43 44
45
41
(a)
(e)
(c or d)
R1R2
PhPh
Ph Ph
Ph Ph
Het
PMB PMB
Het
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36 >10
37 >10
38 >10
39 0.77
a  Radiometric assay using G2019S LRRK2 protein from Invitrogen. The values 
quoted are the mean of at least 2 experiments and with a range of < 25 % of the 
mean.
Scheme 1 illustrates the synthesis of compounds 1-37.9 Grignard 
addition of MeMgBr to 2,4-dichloropyridine-3-carbaldehyde 40 
followed by a Ley-Griffith oxidation gave ketone 41, which was 
reacted with hydrazine to give the chloroheterocycle 42. 
Nucleophilic substitution of 42 with the appropriate amine gave 
the desired 4-amino derivatives 1-17. Ether derivatives 18-25 can 
be prepared by nucleophilic displacement with the corresponding 
sodium alkoxide with microwave heating. Condensation of 41 
with hydroxylamine to the oxime followed palladium mediated 
cyclisation gave 46, which was reacted with cyclohexylamine to 
furnish the 6-azabenzisoxazole derivative 37. Alternatively, 40 
can be converted to 3-iodo-4-chloro-5-azaindazole 43, a versatile 
intermediate enabling variation of both the 3- and 4- positions. To 
facilitate palladium mediated couplings to the 3-iodo group, it was 
necessary to introduce a suitable protecting group to the indazole 
NH as in the absence of protection, the subsequent couplings were 
found to be low yielding. The 4-amino derivatives 26-30 were 
synthesized via nucleophilic displacement of PMB-protected 
intermediate 44, followed by Suzuki-coupling of the appropriate 
boronic acid or boronic ester. Deprotection using TFA gave the 
desired compounds. We found that the PMB-protecting group was 
incompatible with the ether derivatives, as the conditions required 
for removal were too harsh. Much higher yields could be obtained 
from the trityl intermediate 45, as deprotection takes place under 
much milder conditions. Thus 45 can be converted to the 
corresponding 4-alkoxy-5-iodo intermediates, which in turn will 
undergo Suzuki couplings. Finally, deprotection with TFA at 
room-temperature in DCM yielded the desired ether derivatives 
31-35. The N-methyl-5-azaindazole 36 was prepared in 2 steps by 
methylation of 42 followed by displacement with 
cyclohexylamine.
Scheme 2 illustrates the syntheses of the 5-aza-indole 38 and 
the 6-azaindazole 39. The 5-azaindole derivative was prepared 
using a modified Fischer-indole synthesis. Chlorodehydration of 
52 followed by displacement with cyclohexylamine gave 38. 
Commercially available aldehyde 47 was converted to the PMB-
protected 4-chloro-6-azaindazole intermediate 48 in three steps 
using similar chemistry described above. Buchwald coupling of 48 
with cyclohexylamine gave the corresponding PMB-protected 
amine, which was deprotected with aluminium chloride to give 38. 
All final compounds were purified by mass-directed HPLC.  
In conclusion we have optimized a weakly active HTS hit 1 
into a promising lead series of potent and selective LRRK2 
inhibitors with promising DMPK properties. Introduction of 
heterocycles at the 3-position was found to significantly increase 
the potency and kinase selectivity, whilst changes to the 4-
chlorobenzyl group improved the physicochemical properties. The 
compounds also show excellent CNS penetration. LifeArc is a UK 
based technology transfer organization performing translational 
research in collaboration with leading academic groups. These 
compounds were sufficiently promising for a large pharmaceutical 
company to license the series from us and their optimization 
efforts will be discussed in a separate communication.
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